Xconomy National

Archives

by in

Entry	Author	Date	Location
Vertex Vows to Fight On With Alios Drugs in High-Stakes Hepatitis C Race	Luke Timmerman	01/24/12	Boston
Alnylam Cuts One-Third of Workforce, To Save Cash for RNAi Clinical Plans	Luke Timmerman	01/19/12	Boston
Alnylam, Aveo, Biogen, & More Boston Life Sciences Newsmakers	Erin Kutz	01/06/12	Boston
Merck Pours $17M Into Physicians Interactive’s Web Tools for Docs	Arlene Weintraub	01/05/12	Boston
Alnylam Gets First Hint of Effectiveness for RNAi Cholesterol-Lowering Drug	Luke Timmerman	01/04/12	Boston
Merck Leads $10M Funding of HIV Diagnostics Firm Daktari	Arlene Weintraub	01/03/12	Boston
The Top 10 Traffic-Getting Stories at Xconomy San Diego	Bruce V. Bigelow	12/28/11	San Diego
Xconomy Storms NYC: Top Ten Topics in the Big Apple in 2011	Arlene Weintraub	12/27/11	New York
Momenta, Baxter Team Up on Biosimilars	Erin Kutz	12/23/11	Boston
Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs	Luke Timmerman	12/19/11	National
Third Rock Looks to Fight Fat in a New Way, With Ember Therapeutics	Luke Timmerman	12/15/11	Boston
Merck Chemists Use High-Tech Science to Combat Alzheimer’s Disease Challenge	Arlene Weintraub	12/14/11	New York
The Hepatitis C Market: Biotech’s Version of the Daytona 500	Luke Timmerman	12/12/11	National
NanoBio, Merck to Collaborate on Gates-Funded RSV Vaccine	Sarah Schmid	12/09/11	Detroit
Dendreon Pulls In $125M By Selling Royalty Slice of Merck’s Hepatitis C Drug	Luke Timmerman	12/06/11	Seattle
Biogen Idec Boosts Biogenerics Strategy With $300M Samsung Joint Venture	Arlene Weintraub	12/06/11	Boston
Eli Lilly Pumps $4M into IDRI to Continue Hunt for TB Drugs	Luke Timmerman	11/17/11	Seattle
AMAG Stock Rises, Ariad Drug Shows Improved Safety, Rhythm Adds Merck Veteran as CEO, & More Boston-Area Life Sciences News	Erin Kutz	11/11/11	Boston
Merck Unveils Alzheimer’s and Diabetes Projects, Personnel Changes	Arlene Weintraub	11/10/11	New York
Rhythm Adds Former Merck VP as CEO	Erin Kutz	11/09/11	Boston
Biopharma Industry Meetings Could Use Some Fresh Voices	Stewart Lyman	11/01/11	Seattle
Portola Grabs $45M Upfront From Biogen Idec to Develop Autoimmune Drugs	Luke Timmerman	10/27/11	San Francisco
NextBio Sees Growth in Next Market: Physicians Seeking Help Interpreting Individual Genomes	Luke Timmerman	10/18/11	San Francisco
Anadys Pharmaceuticals Surprises the Street, Gets Acquired by Roche for $230M	Luke Timmerman	10/17/11	San Diego
Stem Cell Therapy: A Process With a Promise	Drew McUsic	10/10/11	Seattle
Smoke on the Water: Fireworks at the Cleveland Clinic Medical Innovation Summit	Lisa Suennen	10/10/11	San Francisco
When Will Software for the Genome Take Off? Find out Oct. 24	Luke Timmerman	10/07/11	San Francisco
Celgene Pays Agios $20M, Lycera Adds Cambridge CEO, Getinge Buys Atrium Medical, & More Boston-Area Life Sciences News	Erin Kutz	10/07/11	Boston
Lycera Hires New CEO, Plans Move to U-M Research Center	Sarah Schmid	10/06/11	Detroit
Merck Fine-Tunes Biosimilars Strategy as FDA Guidelines Loom	Arlene Weintraub	10/05/11	New York
Page 1 of 11	next page »